Patents by Inventor Steven C. Quay

Steven C. Quay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180353607
    Abstract: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 13, 2018
    Inventors: Steven C. Quay, Michael E. Houston, Jr., Pierrot Harvie, Roger C. Adami, Renata Fam, Mary Prieve, Kathy Fosnaugh, Shaguna Seth
  • Publication number: 20180200206
    Abstract: Methods and treatments are taught for the treatment of breast disorders, including proliferative breast disease, breast cancer, and increased breast density. The methods and compositions deliver efficacious formulations of chemical and/or biological treatment medicaments to the breast via a transpapillary route.
    Type: Application
    Filed: July 14, 2016
    Publication date: July 19, 2018
    Applicant: Atossa Genetics Inc.
    Inventor: Steven C. Quay
  • Publication number: 20180049999
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one therapeutic agent, a fatty acid mixture comprising at least one omega-3 fatty acid, and at least one vitamin D compound. Also described are methods of preparation of such compositions, and methods of prevention and treatment of breast disorders and estrogen-related disorders.
    Type: Application
    Filed: April 6, 2016
    Publication date: February 22, 2018
    Inventor: Steven C. Quay
  • Patent number: 9731016
    Abstract: This disclosure provides a range of tyrosine amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.
    Type: Grant
    Filed: April 3, 2016
    Date of Patent: August 15, 2017
    Assignee: Marina Biotech, Inc.
    Inventors: Steven C. Quay, Michael E. Houston, Jr., Pierrot Harvie, Roger C. Adami, Renata Fam, Mary Prieve, Kathy Fosnaugh, Shaguna Seth
  • Publication number: 20170145515
    Abstract: The disclosure relates to methods of screening and diagnosing cancer in patients undergoing mammography.
    Type: Application
    Filed: June 2, 2015
    Publication date: May 25, 2017
    Inventors: Shu-Chih CHEN, Steven C. QUAY
  • Publication number: 20160375234
    Abstract: Methods and treatments are taught for the diagnosis and treatment of breast conditions, including proliferative breast disease, ductal hyperplasia, lobular hyperplasia, atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ, lobular carcinoma in situ, lobular carcinoma and invasive breast cancer. The methods and compositions deliver efficacious formulations of chemical and/or biological treatment medicaments to the breast via a transpapillary route.
    Type: Application
    Filed: January 9, 2015
    Publication date: December 29, 2016
    Inventor: Steven C. Quay
  • Publication number: 20160279087
    Abstract: An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of ?-tocotrienol, ?-tocotrienol, ?-tocotrienol, or ?-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg ?-tocotrienol.
    Type: Application
    Filed: March 29, 2016
    Publication date: September 29, 2016
    Inventor: Steven C. Quay
  • Publication number: 20160263217
    Abstract: The disclosure relates to supplement formulations comprising amino acids in ratios that are protein-specific. Described herein is a protein-specific supplement formulation comprising amino acids in the ratio present in the protein's polypeptide sequence. Further described herein is a protein-specific supplement formulation comprising: a base protein and essential amino acids; wherein the relative amounts of amino acids in the formulation match the relative amounts of amino acids naturally occurring in the protein.
    Type: Application
    Filed: October 16, 2014
    Publication date: September 15, 2016
    Inventors: Tara MARTIN-CHEN, Shu-Chih CHEN, Steven C. QUAY
  • Patent number: 9415007
    Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: August 16, 2016
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
  • Publication number: 20160206739
    Abstract: This disclosure provides a range of tyrosine amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.
    Type: Application
    Filed: April 3, 2016
    Publication date: July 21, 2016
    Inventors: Steven C. Quay, Michael E. Houston, JR., Pierrot Harvie, Roger C. Adami, Renata Fam, Mary Prieve, Kathy Fosnaugh, Shaguna Seth
  • Patent number: 9339461
    Abstract: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: May 17, 2016
    Assignee: Marina Biotech, Inc.
    Inventors: Steven C. Quay, Michael E. Houston, Jr., Pierrot Harvie, Roger C. Adami, Renata Fam, Mary G. Prieve, Kathy L. Fosnaugh, Shaguna Seth
  • Patent number: 9295658
    Abstract: An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of ?-tocotrienol, ?-tocotrienol, ?-tocotrienol, or ?-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg ?-tocotrienol.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: March 29, 2016
    Inventor: Steven C. Quay
  • Publication number: 20150323537
    Abstract: Biological samples of mammary fluid or components thereof are obtained using a breast pump device coupled with an absorbent paper or membrane, optionally facilitated by administering oxytocin to the subject. The breast pump device stimulates expression of mammary fluid and provides for collection of diagnostic samples on the absorbent paper or membrane to evaluate breast disease, including cancer. The biological sample may include fluid containing one or more of cells or cellular components, proteins, glycoproteins, peptides, nucleotides or other desired constituents comprising a breast disease marker. Absorbent paper or membrane, and methods relating to the paper or membrane, and a breast pump device are also provided.
    Type: Application
    Filed: May 14, 2015
    Publication date: November 12, 2015
    Inventors: Steven C. Quay, Shu-Chih Chen
  • Publication number: 20150315591
    Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.
    Type: Application
    Filed: May 28, 2015
    Publication date: November 5, 2015
    Applicant: MARINA BIOTECH, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • Publication number: 20150259686
    Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.
    Type: Application
    Filed: May 28, 2015
    Publication date: September 17, 2015
    Applicant: MARINA BIOTECH, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • Publication number: 20150258130
    Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.
    Type: Application
    Filed: May 27, 2015
    Publication date: September 17, 2015
    Applicant: MARINA BIOTECH, INC.
    Inventors: Steven C. Quay, James McSwiggen, Narendra K. Vaish, Mohammad Ahmadian
  • Patent number: 9074205
    Abstract: The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: July 7, 2015
    Assignee: Marina Biotech, Inc.
    Inventors: Steven C. Quay, James Mcswiggen, Narendra K. Vaish, Mohammad Ahmadian
  • Patent number: 9052318
    Abstract: Biological samples of mammary fluid or components thereof are obtained using a breast pump device coupled with an absorbent paper or membrane, optionally facilitated by administering oxytocin to the subject. The breast pump device stimulates expression of mammary fluid and provides for collection of diagnostic samples on the absorbent paper or membrane to evaluate breast disease, including cancer. The biological sample may include fluid containing one or more of cells or cellular components, proteins, glycoproteins, peptides, nucleotides or other desired constituents comprising a breast disease marker. Absorbent paper or membrane, and methods relating to the paper or membrane, and a breast pump device are also provided.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: June 9, 2015
    Assignee: ATOSSA GENETICS, INC.
    Inventors: Steven C. Quay, Shu-Chih Chen
  • Patent number: 9023793
    Abstract: Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: May 5, 2015
    Assignee: Retrophin, Inc.
    Inventors: Alexis Kays Leonard, Joshua Orion Sestak, Henry R. Costantino, Anthony P. Sileno, Lalit Raj Peddakota, Kayvon Emile Sharghi, Garland M. Bellamy, Jason Philip Gesty, Steven C. Quay
  • Publication number: 20150065362
    Abstract: Disclosed herein are computer-based systems, media and methods of generating dynamic classifiers and uses thereof. The dynamic classifiers may be generated from a subset of cases and/or a subset of genes that have a molecular similarity to a subject suffering from a cancer. Thus, the dynamic classifiers may be subject-specific. The dynamic classifiers may be used in the diagnosis, prognosis and/or monitoring of a status or outcome of a cancer in a subject in need thereof.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Inventors: Balázs Gyorffy, Steven C. Quay, Shu-Chih Chen